Evaluating the Efficacy, Safety, and Clinical Application of Biktarvy as a Therapeutic Regimen for HIV-1 Infection

This article examines the real-world effectiveness, long-term safety, and label change of the HIV medication Biktarvy.

The BICSTaR study provides evidence of Biktarvy's efficacy and safety, showing sustained impact regardless of prior treatment and comorbidity status. The study includes a diverse population, considering various factors such as age, race, sex, adherence, and late diagnosis.

The five-year data from Phase 3 studies solidify the robust and durable efficacy of Biktarvy, with minimal adverse events reported.

Overall, Biktarvy offers a comprehensive and well-tolerated treatment option for individuals with HIV.

Real-World Effectiveness of Biktarvy

The real-world effectiveness of Biktarvy, an HIV medication, has been demonstrated through the BICSTaR study and long-term data from Phase 3 studies, solidifying its efficacy and safety profile.

The BICSTaR study provided real-world evidence of Biktarvy's effectiveness and safety in a diverse population of people with HIV across nine countries. The study considered various factors such as age, race, sex, adherence, and late diagnosis. The findings showed high viral suppression rates at 24 months, both in treatment-naïve and treatment-experienced participants. Additionally, there were low rates of treatment discontinuations and few drug-related adverse events reported.

Moreover, long-term data from Phase 3 studies 1489 and 1490 further supported the robust and durable efficacy and safety profile of Biktarvy. Participants who switched from a dolutegravir-containing regimen to Biktarvy experienced sustained viral suppression. The data demonstrated high efficacy and safety at Week 240, with minimal adverse events reported during the open-label extension phase. Notably, there were no renal discontinuations reported.

Long-Term Safety and Efficacy Profile

Biktarvy's safety and efficacy profile has been solidified through five-year data from Phase 3 studies and demonstrates its robust and durable performance in individuals with HIV.

Real-world data from the BICSTaR study further supports the effectiveness of Biktarvy in diverse populations with HIV, regardless of prior treatment and comorbidity status. The study includes participants from nine countries, considering factors such as age, race, sex, adherence, and late diagnosis.

High viral suppression rates were observed in both treatment-naïve and treatment-experienced individuals at 24 months, with low treatment discontinuations and few drug-related adverse events reported.

Moreover, the long-term safety and efficacy of Biktarvy were demonstrated in participants up to Week 240, with minimal adverse events reported during the open-label extension phase and no renal discontinuations reported.

These findings reinforce the real-world effectiveness of Biktarvy in individuals with HIV, including those with a high level of comorbidities.

The high treatment outcomes and patient satisfaction observed in clinical trials and real-world data highlight the importance of Biktarvy in supporting long-term health discussions and improving the quality of life for individuals with HIV.

Real-World Effectiveness Across Populations With Comorbidities

Real-world data from the BICSTaR study solidifies the real-world effectiveness of Biktarvy in diverse populations with comorbidities. This study provides valuable insights into how comorbidities impact treatment outcomes for individuals with HIV. The findings from the BICSTaR study are consistent with evidence from randomized clinical trials, further supporting the efficacy of Biktarvy in real-world settings.

The study included a diverse population across nine countries, taking into consideration factors such as age, race, sex, adherence, and late diagnosis. The data demonstrated that Biktarvy provides sustained viral suppression for people with HIV, even in those with comorbidities. This is crucial for the long-term health of individuals living with HIV, as comorbidities can often complicate treatment outcomes.

Furthermore, the study showed low rates of treatment discontinuations and drug-related adverse events, indicating that Biktarvy is generally well-tolerated in individuals with comorbidities. These findings highlight the importance of innovation and improvement in HIV treatment options, as they can greatly support long-term health discussions and improve the overall quality of life for people with HIV.

Label Change and Regulatory Approval

The U.S. Food and Drug Administration (FDA) authorized a label change for Biktarvy on October 14, 2022. This label update includes efficacy data from 144 weeks and safety data from 240 weeks of clinical trial data. The approval was based on studies 1489 and 1490, which demonstrated Biktarvy's long-term safety and efficacy in adults with HIV.

In adults and pediatric patients with HIV-1 infection, Biktarvy is indicated as a complete regimen. It can be used as initial treatment or as a substitute for the current antiretroviral regimen in virologically suppressed individuals.

The clinical trials showed that Biktarvy had high efficacy in both treatment-naïve patients and virologically suppressed patients who switched to the drug. In treatment-naïve patients, Biktarvy achieved a viral load of less than 50 copies/mL in 92-93% of patients at Week 48. In virologically suppressed patients, Biktarvy maintained virologic suppression in 92-95% of patients at Week 48. The drug was well-tolerated in both patient groups, with minimal adverse events reported.

The label change and regulatory approval for Biktarvy provide healthcare providers and patients with updated information on the drug's long-term safety and efficacy. This information is essential for making informed decisions about HIV treatment options. The FDA approval reinforces the reliability and effectiveness of Biktarvy as a treatment option for individuals with HIV.

Characteristics and Components of Biktarvy

Biktarvy, an HIV medication, is characterized by its unique combination of three powerful antiviral drugs. It is a complete HIV treatment that combines the unboosted integrase strand transfer inhibitor (INSTI) bictegravir with the Descovy backbone (emtricitabine/tenofovir alafenamide). This makes it the smallest 3-drug, INSTI-based single-tablet regimen available. One of the key characteristics of Biktarvy is its simple once-daily dosing, which can be taken with or without food. Additionally, Biktarvy has a limited drug interaction potential and a high barrier to resistance.

The efficacy of Biktarvy has been demonstrated in clinical trials. In treatment-naïve patients, the drug showed high efficacy in achieving viral suppression, with viral loads of less than 50 copies/mL observed in 92-93% of patients at Week 48. The drug was also well-tolerated in this patient population. Similarly, in virologically-suppressed patients who switched to Biktarvy, the drug maintained virologic suppression in 92-95% of patients at Week 48. Again, the drug was well-tolerated in this patient population.

Subgroup analysis in clinical trials showed consistent efficacy of Biktarvy across different patient groups, including men and women, non-Black and Black patients, and patients below or above certain age thresholds. The drug demonstrated consistent efficacy in various patient subgroups.

While Biktarvy is generally well-tolerated, there are possible side effects that patients should be aware of. These include worsening of hepatitis B infection, immune reconstitution syndrome, kidney problems, and build-up of lactic acid in the blood. Headaches, diarrhea, and nausea are the most commonly reported side effects.

Conclusion

In conclusion, Biktarvy has demonstrated real-world effectiveness, long-term safety and efficacy, and regulatory approval for the treatment of HIV.

The BICSTaR study and Phase 3 data provide strong evidence of its sustained viral suppression and minimal adverse events.

The label change approved by the FDA further supports its long-term efficacy in adults with HIV.

With its comprehensive and well-tolerated characteristics, Biktarvy offers a valuable treatment option for individuals with HIV.

Bibliography

Peters, Ellen. "Efficacy, Safety and Tolerability of Biktarvy in HIV-1 Infection: A Scoping Review - Ellen Peters, and Collins Iwuji, 2023." Antiviral Therapy, 2023, (https://journals.sagepub.com/doi/full/10.1177/13596535231159030)
"Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living with HIV with a Range of Comorbidities." Gilead.com, 2022, (https://www.gilead.com/news-and-press/press-room/press-releases/2022/10/gilead-presents-real-world-evidence-reinforcing-the-use-of-biktarvy-for-the-treatment-of-people-living-with-hiv-with-a-range-of-comorbidities)
Center. "Drug Trials Snapshot: BIKTARVY." U.S. Food and Drug Administration, 2020, (https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-biktarvy)
Parmar, Kanak, et al. "A Possible Case of Bictegravir-Associated Severe Unconjugated Hyperbilirubinemia." Aids Research and Therapy, vol. 20, no. 1, BioMed Central, Jan. 2023, (https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-023-00501-7)